Vir Biotechnology, Inc. (VIR) Form SCHEDULE 13D/A — Nov 6, 2026
ARCH Venture Fund IX and ARCH Venture Fund IX Overage sold a combined 796,175 shares of Vir Biotechnology common stock between November 3 and November 5, 2026, at weighted average prices between $11.24 and $12.06 per share. After the sales, the ARCH funds beneficially own 11,897,988 shares, about 6.9% of Vir's 171,270,773 shares outstanding as of October 28, 2026. Related ARCH managing directors Robert Nelsen, Keith Crandell, and Clinton Bybee each report ~7%+ stakes on a shared basis.
Key figures
- Shares Outstanding
- 171270773
- Shares sold avf ix
- 347819
- Percent owned bybee
- 7%
- Percent owned funds
- 6.9%
- Weighted avg prices
- ["$11.24","$11.60","$11.26","$12.06"]
- Avf ix record shares
- 5055689
- Percent owned nelsen
- 7.3%
- Sale price range low
- 10.98
- Sale price range high
- 12.16
- Percent owned crandell
- 7.1%
- Ix overage record shares
- 6842299
- Shares sold avf ix overage
- 448356
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.